Double-blind, placebo-controlled, dose-escalating phase 1 trial of LCB10 0200 (GT-1) in healthy volunteers

Trial Profile

Double-blind, placebo-controlled, dose-escalating phase 1 trial of LCB10 0200 (GT-1) in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs LCB10-0200 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Sep 2017 According to a Geom Therapeutics media release, the company is planning to initiate Phase 1 studies in 2018.
    • 18 Sep 2017 New trial record
    • 13 Sep 2017 According to a Geom Therapeutics media release, company plans to submit an IND to the FDA in 2H 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top